Respuesta a olanzapina en episodios de inicio y recurrencias precoces de la esquizofreniaun estudio observacional

  1. J.M. Montes Rodríguez 1
  2. J. Saiz Ruiz 1
  3. A. Ibáñez Cuadrado 1
  4. C. Pelegrín Valero 2
  5. D. Huertas Sánchez 1
  6. F. Vicente Martín 3
  7. M. Díaz Marsá 4
  8. F. Arias Horcajadas 5
  9. D. Jiménez Morón 6
  10. M. García Toro 7
  11. V. Fabregat Navarro 8
  12. I. Moreno Oliver 9
  13. M.P. Morales Socorro 10
  1. 1 Universidad de Alcalá
    info

    Universidad de Alcalá

    Alcalá de Henares, España

    ROR https://ror.org/04pmn0e78

  2. 2 Hospital Miguel Servet. Zaragoza
  3. 3 CSM Latina. Hospital Clínico. Madrid
  4. 4 Hospital Fundación de Alcorcón. Madrid
  5. 5 Centro Regional de Salud Pública de Talavera
  6. 6 Hospital Son Llatzer. Palma de Mallorca
  7. 7 Hospital San Lázaro, Madrid
  8. 8 Hospital de Mollet. Barcelona
  9. 9 Hospital Nuestra Señora del Perpetuo Socorro. Albacete
  10. 10 Hospital Provincial de Toledo.
Show affiliations +
Journal:
Psiquiatría biológica: Publicación oficial de la Sociedad Española de Psiquiatría Biológica

ISSN: 1134-5934

Year of publication: 2003

Volume: 10

Issue: 3

Pages: 73-80

Type: Article

DIALNET GOOGLE SCHOLAR

More publications in: Psiquiatría biológica: Publicación oficial de la Sociedad Española de Psiquiatría Biológica

Abstract

Background: Antipsychotic treatment in the first episode of schizophrenia should quickly produce the greatest possible degree of remission and be well-tolerated to prevent lack of compliance. This aids the rehabilitation process that improves psychosocial functioning. The aim of this study was to evaluate the safety, tolerance and efficacy of olanzapine in the treatment of first episodes of schizophrenia, schizophreniform disorder and schizophrenia recurrences without residual symptomatology. Patients and methods: Thirty-five patients were treated with olanzapine according to daily clinical practice for a 6-month period. Clinical status was evaluated through the Brief Psychiatric Rating Scale (BPRS), the Clinical Global Impression Scale (CGI) for severity of illness and improvement, and the Global Assessment of Functioning Scale (GAF). Results: Fourteen patients (40%) showed no adverse events (n = 14). The most frequent adverse events were weight gain (22.9%) and sedation (14.3%). A total of 74.36% of the patients showed no extrapyramidal symptoms and none required antiparkinsonian medication. Twenty-five patients (71.4%) responded well to olanzapine (a reduction in BPRS of more than 40% or a score of <18 together with CGI improvement of 1 or 2). No difference in clinical response was found among the three diagnostic groups in the study. Conclusions: In this naturalistic study, olanzapine was safe and effective in the treatment of first episodes of schizophrenia, schizophreniform disorder and acute episodes of schizophrenia. There were few extrapyramidal effects, which may favor compliance and consequently the course of the illness.

Data source: Dialnet